Home Cholesterol Monitors — CPB 0367 | AETNA Coverage Update

Aetna modified CPB 0367 governing home cholesterol monitor coverage, effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0367, which governs coverage for home cholesterol monitors billed under HCPCS A9279. This change affects billing teams working with patients diagnosed with lipid metabolism disorders across the E71, E75, E77, E78, and E88 code ranges, as well as screening encounters coded Z13.220. If your practice or DME supplier bills A9279 for Aetna members, audit your charge capture and diagnosis coding before submitting claims against this updated coverage policy.

Quick-Reference Table

Aetna Home Cholesterol Monitor Coverage Criteria and Medical Necessity Requirements 2025

CPB 0367 Aetna is the Clinical Policy Bulletin that controls whether a home cholesterol monitor billed under HCPCS A9279 gets paid or denied. The policy links coverage directly to a documented diagnosis — specifically, a recognized disorder of lipoid metabolism or a qualifying screening encounter.

The 39 ICD-10-CM codes listed in this policy define the boundary of covered use. Most fall under the E75, E77, and E78 families, which cover a wide range of lipid storage diseases, lipoprotein deficiencies, hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia. E88.1 (lipodystrophy) and E88.2 (lipomatosis) are also included, along with Z13.220 for lipid disorder screening encounters.

Medical necessity under this coverage policy means the patient must carry one of these diagnoses. A claim for A9279 without a matching covered diagnosis code will not establish medical necessity under CPB 0367. That's not a gray area — it's a straight denial.

The real issue here is specificity. The E78 family alone includes 15 codes in this policy, from E78.0 (pure hypercholesterolemia) through E78.9 (unspecified hyperlipidemia). If your billing team is defaulting to E78.5 (hyperlipidemia, unspecified) out of habit, that code is covered under this policy — but you should still ask whether the documentation supports a more specific code. Aetna's utilization management teams look for specificity mismatches, and sloppy coding on DME claims draws attention.

Prior authorization requirements for A9279 under this policy are not explicitly detailed in the published CPB summary. That does not mean prior auth is waived. Check the member's specific plan benefits before billing — Aetna commercial and Aetna Medicare Advantage plans can have different prior authorization thresholds for durable medical equipment and monitoring devices. If you're unsure, contact Aetna Provider Services or pull the member's plan details through Aetna's provider portal before the claim goes out.

Home cholesterol monitor billing sits in an interesting gray zone for reimbursement. A9279 is a broad HCPCS code — "monitoring feature/device, stand-alone or integrated, any type, includes all accessories and components." That breadth is both useful and dangerous. It covers a wide range of devices, but it also means your documentation needs to be airtight about what device was supplied and why it was medically necessary for that specific patient.

Aetna Home Cholesterol Monitor Exclusions and Non-Covered Indications

The published CPB 0367 summary does not explicitly enumerate experimental or non-covered indications. However, the policy's structure is a positive coverage list — meaning only the 39 ICD-10-CM codes listed are recognized as covered diagnoses. Any claim for A9279 paired with a diagnosis outside that list is outside the scope of this coverage policy.

This matters for billing teams handling patients with borderline or comorbid diagnoses. If a patient has obesity (E66.xx) or metabolic syndrome without a co-listed lipid disorder code, that diagnosis alone does not establish coverage under CPB 0367. You need a covered lipoid metabolism diagnosis on the claim.

Molecularly imprinted membrane monitors are referenced in the A9279 code description under this policy. The policy groups them with standard home cholesterol monitors under HCPCS A9279. If your supplier is billing for a more advanced monitoring technology, confirm it maps to A9279 and that the clinical documentation supports the underlying diagnosis.

Coverage Indications at a Glance

Aetna Home Cholesterol Monitor Billing Guidelines and Action Items 2025

1. Audit your ICD-10 diagnosis pairings for A9279 before September 26, 2025.
Pull every open or pending claim for HCPCS A9279 billed to Aetna. Confirm each claim includes at least one of the 39 covered ICD-10-CM codes from CPB 0367. Any claim without a covered diagnosis is a claim denial waiting to happen.

2. Stop defaulting to E78.5 without checking documentation.
E78.5 (hyperlipidemia, unspecified) is on the covered list, but it's also the code auditors flag first. If the physician documentation supports E78.0, E78.2, or another specific lipid disorder, use the specific code. Unspecified codes invite scrutiny on DME claims.

3. Confirm prior authorization requirements at the plan level — not just the policy level.
CPB 0367 is Aetna's clinical policy, but individual plan riders can layer on prior authorization requirements that the CPB doesn't mention. Check the member's plan benefits for A9279 before billing. This is especially true for Aetna Medicare Advantage plans, which often have different DME authorization thresholds than commercial plans.

4. Update your charge capture to include the full 39-code ICD-10 list from CPB 0367.
If your billing system uses a short-list of common lipid disorder codes, expand it. The policy covers codes from E71.30 through E88.89, including several less common sphingolipidoses and glycoprotein degradation disorders (E75.21, E75.240–E75.249, E77.0–E77.9). Patients with these diagnoses are covered — your system needs to recognize that.

5. Review documentation for the Z13.220 (lipid disorder screening) indication carefully.
Aetna includes Z13.220 as a covered diagnosis for home cholesterol monitor billing. But screening indications for DME devices are an area where plan-level benefits can diverge from clinical policy. Confirm the member's plan covers home monitoring devices for screening purposes, not just active treatment. A reimbursement denial on a screening claim is a common billing team surprise with DME.

6. If you're billing for molecularly imprinted membrane monitors, verify your A9279 mapping.
The code description in CPB 0367 specifically references molecularly imprinted membrane monitors alongside standard home cholesterol monitors. Both map to A9279. Make sure your charge description master (CDM) reflects this and that your clinical documentation specifies the device type.

7. Talk to your compliance officer if your DME volume for A9279 is high.
This policy modification is a signal that Aetna is actively maintaining its home cholesterol monitor billing guidelines. High A9279 volume without tight diagnosis pairing and documentation practices is a claim denial and audit risk. If your practice or supplier bills significant DME volume for Aetna members, loop in your compliance officer before the effective date of September 26, 2025.

CPT, HCPCS, and ICD-10 Codes for Home Cholesterol Monitors Under CPB 0367

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

Key ICD-10-CM Diagnosis Codes